贝伐单抗联合TP化疗方案对复发性宫颈癌患者血清肿瘤标志物及生存周期的影响

Effect of cisplatin-paclitaxel chemotherapy with bevacizumab on serum tumor markers and survival time in recurrent cervical cancer

目的 观察贝伐单抗联合TP化疗方案对复发性宫颈癌患者血清肿瘤标志物及生存周期的影响.方法 60例复发性宫颈癌患者随机分为对照组和实验组,分别给予TP化疗+贝伐单抗或单独TP化疗,比较两组治疗效果、血清肿瘤标志物水平、生存周期、不良反应.结果 实验组疗效优于对照组(P<0.05),血清鳞状细胞癌抗原、糖链抗原CA15-3、癌胚抗原水平及血小板减少发生率低于对照组(P<0.01);中位生存期和无进展生存期长于对照组(P<0.05).结论 贝伐单抗联合TP化疗方案治疗复发性宫颈癌安全、有效,可降低血清肿瘤标志物水平,延长生存周期.

Objective To observe the effect of cisplatin-paclitaxel chemotherapy with bevacizumab on serum tumor markers and survival time in recurrent cervical cancer.Methods Sixty patients with recurrent cervical cancer were randomly treated with cisplatin-paclitaxel chemotherapy with(experimental group)or without(control group)bevacizumab.Clinical efficacy,serum tumor markers,survival time,and adverse reactions were compared between two groups.Results Compared with control group,clinical efficacy,median survival and progression-free survival were higher(P<0.05),while serum levels of squamous cell carcinoma antigen,CA15-3,and carcinoembryonic antigen,and incidence of thrombocytopenia were lower(P<0.01)in experimental group.Conclusion Cisplatin-paclitaxel chemotherapy with bevacizumab can reduce serum tumor markers,prolong survival time,which is effective and safe for recurrent cervical cancer.